Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

31.78 -0.26 (-0.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel 
Via Benzinga
Exposures Product Safety
Analyst Ratings For Legend Biotech
Via Benzinga
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
From Legend Biotech Corporation
Via Business Wire
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population
FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration... 
Via Benzinga
Exposures Product Safety
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
Unveiling 9 Analyst Insights On Legend Biotech
Via Benzinga
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy
Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend’s Carvykti is expected to hit annual... 
Via Benzinga
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
From Legend Biotech Corporation
Via Business Wire
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &... 
Via Benzinga
Exposures Product Safety
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers
Join the FDA's Oncologic Drugs Advisory Committee on March 15th to review Johnson & Johnson/Legend Biotech's Carvykti application for relapsed/refractory multiple myeloma treatment. Delve into... 
Via Benzinga
Exposures Product Safety
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday. 
Via Benzinga
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
Earnings Scheduled For March 11, 2024
Companies Reporting Before The Bell • Ballard Power Systems (NASDAQ:BLDP) is estimated to report quarterly loss at $0.13 per share on revenue of $34.20 million. 
Via Benzinga
Earnings Preview: Legend Biotech
Via Benzinga
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the... 
Via Talk Markets
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales. 
Via Benzinga
What 4 Analyst Ratings Have To Say About Legend Biotech
Via Benzinga
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
Shanghai AlphaGen Therapeutics and ArtBio forged a far-reaching agreement to expand ArtBio’s market and develop new radioligand therapies. Additionally, Biocytogen Pharma signed an antibody... 
Via Talk Markets
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
From Legend Biotech Corporation
Via Business Wire
Key Takeaways From Legend Biotech Analyst Ratings
Via Benzinga
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results
From Legend Biotech Corporation
Via Business Wire
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.  
Via Benzinga
Exposures Product Safety
As China's Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks?
Exploring the economic implications of China's declining population on property markets and the potential rise of healthcare and tech investments. 
Via Benzinga
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction... 
Via Benzinga
Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3
From Legend Biotech Corporation
Via Business Wire
Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Legend Biotech Corporation
Via Business Wire
Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback
Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals. 
Via Benzinga
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)
From Legend Biotech Corporation
Via Business Wire
Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say
Friday, Arcellx Inc (NASDAQ: ACLX) announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel) for relapsed and/or  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.